Eritropoyetina o darbepoyetina para los pacientes con cáncer
Información
- DOI:
- https://doi.org/10.1002/14651858.CD003407.pub5Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 12 diciembre 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Hematología
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Thomy Tonia: Quality of Life analysis, searching for trials, eligibility and quality assessment, fact checking, data extraction and analysis, drafting of QoL and discussion, revision of review
Annette Mettler: Searching for trials, eligibility and quality assessment, data extraction and analysis
Nadège Robert: Searching for trials, eligibility and quality assessment, data extraction and analysis
Guido Schwarzer: Statistical and methodological advice, data analysis, content input
Olaf Weingart: eligibility and quality assessment, fact checking, creating summary of findings table
Jerome Seidenfeld: Clinical and scientific advice, content input, revision of draft review
Chris Hyde: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis
Andreas Engert: Clinical and scientific advice, content input
Julia Bohlius: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting and revision of review
Sources of support
Internal sources
-
Department of Internal Medicine I, University of Cologne, Germany.
-
Cochrane Haematological Malignancies Group (CHMG), Germany.
-
Institute of Social and Preventive Medicine, University of Bern, Switzerland.
External sources
-
Department of Health, UK.
Declarations of interest
Thomy Tonia, Annette Mettler, Nadège Robert, Olaf Weingart, Guido Schwarzer, Jerome Seidenfeld, Chris Hyde, Andreas Engert, Julia Bohlius: none known.
Acknowledgements
We thank all authors and co‐workers of primary studies, for which additional information and study data were provided: R. Abels, K. Aziz, J. Blohmer, D. Case, S. Cascinu, M. Cazzola, C. Coiffier, F. Dammacco, L. Del Mastro, D. Henry, Italian Cooperative Study Group, C. Kurz, T. Littlewood, V. Moebus, C. Oberhoff, A. Österborg, E. Rose, W. Ten Bokkel, N. Thatcher, JA. Thompson, NA. Throuvalas, A. Varan. We thank the pharmaceutical companies for providing us with data for various studies (Roche) and admitted additionally insight into their clinical study reports (OrthoBiotech). We also thank the pharmaceutical companies for being very helpful in answering our questions during the process of this previous versions of this review (Roche, Johnson & Johnson).
We would like to thank all previous co‐authors who contributed to previous versions of this review: Simon Langensiepen, Jayne Wilson, Margaret Piper; Sven Trelle, Susan Bayliss, Susan Brunskill, Josie Sandercock, Ben Djulbegovic, Charles Bennett.
Special thanks to Pia Raanani and Sue Richards (CHMG editors) as well as Maryann Napoli (Consumer) and Nicole Skoetz (CHMG editorial base) for critical advice and strong support of previous and current versions of this review.
The first and the second update of this review was supported by the UK Department of Health Cochrane Review Update Incentive Scheme.
Version history
| Published | Title | Stage | Authors | Version |
| 2012 Dec 12 | Erythropoietin or darbepoetin for patients with cancer | Review | Thomy Tonia, Annette Mettler, Nadège Robert, Guido Schwarzer, Jerome Seidenfeld, Olaf Weingart, Chris Hyde, Andreas Engert, Julia Bohlius | |
| 2006 Jul 19 | Erythropoietin or Darbepoetin for patients with cancer | Review | Julia Bohlius, Jayne Wilson, Jerome Seidenfeld, Margret Piper, Guido Schwarzer, Josie Sandercock, Sven Trelle, Olaf Weingart, Susan Bayliss, Susan Brunskill, Benjamin Djulbegovic, Charles Bennett, Simon Langensiepen, Chris Hyde, Andreas Engert | |
| 2005 Oct 19 | Erythropoietin for patients with malignant disease | Review | Julia Bohlius, Simon Langensiepen, Guido Schwarzer, Jerome Seidenfeld, Margret Piper, C Bennet, Andreas Engert, Charles Bennett | |
| 2004 Jul 19 | Erythropoietin for patients with malignant disease | Review | Julia JB Bohlius, Simon Langensiepen, Guido Schwarzer, J Seidenfeld, Margret Piper, C Bennet, Andreas Engert, Charles Bennett | |
| 2002 Apr 22 | Erythropoietin for patients with malignant disease | Protocol | Simon SL Langensiepen, Julia Bohlius, Jerome Seidenfeld, Margret Piper, C Bennett, Guido Schwarzer, Andreas Engert, Charles Bennet | |
Differences between protocol and review
In previous versions of this review, we required dosages of at least 300 U/kg body weight per week (epoetin‐a and beta) given for at least four weeks. For the current update this criterion was removed and we included studies or study arms with low dosages as well. In previous versions of this review, iron supplementation had to be identical in the study arms of a given trial. For the current update, we changed this criterion and included trials using iron supplementation in the experimental but not in the control arm as well.
